Newsroom | 68958 results
Sorted by: Latest
-
SunnyFit Celebrates 4-Year Anniversary with “Year 4 Everyone” Challenge and Community Giveaway Event
INDUSTRY, Calif.--(BUSINESS WIRE)--SunnyFit, the free fitness app developed by Sunny Health & Fitness, is celebrating its fourth anniversary with the Year 4 Everyone Challenge & Giveaways Event, running from March 6 through March 26, 2026. The celebration highlights the platform’s growing global community of nearly half a million users and introduces a series of challenges, rewards, and prize giveaways. The anniversary celebration will conclude with the Year 4 Everyone Livestream &...
-
Riassunto: Incyte presenterà gli ultimi dati sull'idrosadenite suppurativa (HS) al Meeting annuale 2026 della American Academy of Dermatology (AAD)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha annunciato che i dati provenienti da programmi importanti nella sua serie franchise Inflammation and Autoimmunity (IAI) verranno presentati al Meeting annuale 2026 della American Academy of Dermatology (AAD), che si svolgerà a Denver dal 27 al 31 marzo 2026. “All'AAD 2026, presenteremo gli ultimi risultati ottenuti in 54 settimane dal programma di Fase 3 STOP‑HS di valutazione del povorcitinib nell'idrosadenite suppurativa (HS)”, h...
-
Incyte présentera des données de dernière minute sur l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD)
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq : INCY) a annoncé aujourd’hui que les données issues des programmes clés de sa division Inflammation et Auto-immunité (IAI) seront présentées lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD), qui se tiendra du 27 au 31 mars 2026 à Denver. « Lors de l’AAD 2026, nous présenterons les derniers résultats à 54 semaines du programme de phase 3 STOP-HS évaluant le povorcitinib dans l’hidradénite suppurée (HS) », déclare Ji...
-
Incyte wird auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) die neuesten Daten aus der Hidradenitis suppurativa-Forschung vorstellen
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) gab heute die Vorstellung von Daten aus Schlüsselprogrammen seines Franchise-Bereichs Entzündungen und Autoimmunität (Inflammation and Autoimmunity, IAI) auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) bekannt, die vom 27. bis 31. März 2026 in Denver stattfinden wird. „Auf der AAD 2026 werden wir die neuesten 54-Wochen-Ergebnisse aus dem Phase-3-STOP-HS-Programm zur Bewertung von Pavorcitinib bei Hidradenitis suppur...
-
Incyte presentará los últimos datos sobre la hidradenitis supurativa en el Congreso Anual de la Academia Estadounidense de Dermatología (AAD) de este año
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) ha anunciado hoy que los datos de los programas primordiales de su franquicia de Inflamación y Autoinmunidad (IAI) se presentarán en el Congreso Anual de la Academia Estadounidense de Dermatología (American Academy of Dermatology, AAD) de 2026, que se realizará del 27 al 31 de marzo de 2026, en Denver. "En la AAD 2026, presentaremos los últimos resultados a las 54 semanas del programa de fase III STOP-HS, que evalúa la administración d...
-
Samenvatting: Incyte belicht meest recente gegevens met betrekking tot hidradenitis suppurativa tijdens de 2026 AAS (American Academy of Dermatology) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) maakte vandaag bekend dat gegevens uit belangrijke programma's in haar IAI-franchise (Inflammation & Autoimmunity) zullen worden voorgesteld tijdens de 2026 AAS (American Academy of Dermatology) Annual Meeting, die van 27 tot 31 maart 2026 doorgaat in Denver. “Op AAD 2026 stellen we zeer recente resultaten uit de 54 weken voor van het Fase 3 STOP‑HS programma, waarin povorcitinib wordt geëvalueerd bij hidradenitis suppurativa (HS),” ve...
-
Fortis Healthcare remporte six distinctions de premier plan au sommet FICCI Advantage Healthcare India 2026 et renforce le leadership médical mondial de l'Inde
NEW DELHI--(BUSINESS WIRE)--Fortis Healthcare vient de recevoir six prix prestigieux au FICCI Advantage Healthcare India 2026, le sommet international sur les voyages médicaux , soulignant son leadership et son excellence dans la prestation de soins de santé à l'échelle mondiale. Ces distinctions, présentées lors du sommet de trois jours qui s’est tenu du 23 au 25 février 2026 dans le cadre des FICCI Medical Value Travel Awards, consolident la réputation de Fortis en tant que partenaire de conf...
-
Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology
SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of NAMs in Neuromuscular Pharmacology...
-
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)...
-
TekSynap Awarded Position on GSA’s Alliant 3 GWAC
RESTON, Va.--(BUSINESS WIRE)--TekSynap is proud to announce it has been awarded a position on the General Services Administration’s Alliant 3 Governmentwide Acquisition Contract, a Best-in-Class, pre-competed, multiple-award contract vehicle designed to help federal agencies acquire complex enterprise IT services and solutions with speed, consistency, and value. GSA announced the phase 1 awards on February 20, 2026, and the vehicle went live for ordering on March 10, 2026. Alliant 3 expands ear...
